Octreotide Acetate Injection, Solution
FDA Label NDC 0641-6174

47 label sections · Submitted to the FDA by Hikma Pharmaceuticals Usa Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Hikma Pharmaceuticals Usa Inc. for the product Octreotide Acetate (NDC 0641-6174). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding recent major changes, 1.1 acromegaly, 1.2 carcinoid tumors, 1.3 vasoactive intestinal peptide tumors, 1.4 important limitations of use, 2.1 dosage and administration overview, 2.2 recommended dosage and monitoring for acromegaly, 2.3 recommended dosage and monitoring for carcinoid tumors, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.